CY1110207T1 - PHARMACEUTICAL AND NALTREXON MEDICINAL COMBINATIONS - Google Patents

PHARMACEUTICAL AND NALTREXON MEDICINAL COMBINATIONS

Info

Publication number
CY1110207T1
CY1110207T1 CY20101100649T CY101100649T CY1110207T1 CY 1110207 T1 CY1110207 T1 CY 1110207T1 CY 20101100649 T CY20101100649 T CY 20101100649T CY 101100649 T CY101100649 T CY 101100649T CY 1110207 T1 CY1110207 T1 CY 1110207T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical
naltrexon
medicinal combinations
medicinal
combinations
Prior art date
Application number
CY20101100649T
Other languages
Greek (el)
Inventor
Benjamin Oshlack
Curtis Wright
Chris Breder
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04788669A external-priority patent/EP1663229B1/en
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1110207T1 publication Critical patent/CY1110207T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Αποκαλύπτεται μια φαρμακευτική σύνθεση η οποία περιλαμβάνει από περίπου 5 έως περίπου 20 mg υδροκοδώνης ή φαρμακευτικά αποδεκτού άλατός της και από 0,055 έως περίπου 0,56mg ναλτρεξόνης ή φαρμακευτικά αποδεκτού άλατός της.A pharmaceutical composition is disclosed comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg of naltrexone or a pharmaceutically acceptable salt thereof.

CY20101100649T 2003-09-25 2010-07-09 PHARMACEUTICAL AND NALTREXON MEDICINAL COMBINATIONS CY1110207T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50622203P 2003-09-25 2003-09-25
EP04788669A EP1663229B1 (en) 2003-09-25 2004-09-09 Pharmaceutical combinations of hydrocodone and naltrexone

Publications (1)

Publication Number Publication Date
CY1110207T1 true CY1110207T1 (en) 2015-01-14

Family

ID=42664692

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100649T CY1110207T1 (en) 2003-09-25 2010-07-09 PHARMACEUTICAL AND NALTREXON MEDICINAL COMBINATIONS

Country Status (1)

Country Link
CY (1) CY1110207T1 (en)

Similar Documents

Publication Publication Date Title
ATE464049T1 (en) PHARMACEUTICAL COMBINATIONS OF HYDROCODONE AND NALTREXONE
ATE419039T1 (en) PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
CY1116693T1 (en) A combination of azelastin and cycloneside
EA200301165A1 (en) Drug on the basis of oxycodone
CY1119381T1 (en) 2-Methylmorpholine Pyridine-, Pyrazo- and Pyrimidine Pyrimidine Derivatives as MTOR Suspensions
CY1106697T1 (en) N-SUBSTITUTED HYDROMORPHONES AND THEIR USE
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
CY1106386T1 (en) SUBSTITUTED 3-PYRROLIDINE-INDOLE DERIVATIVES
CY1111797T1 (en) LOCAL PHARMACEUTICAL FORM FOR IVERMECTIN FOR DERMATOLOGICAL TREATMENT
DE602004031771D1 (en) OPERATING FORM OF OPIATS FOR ORAL USE AND METHOD FOR THE ADMINISTRATION OF OXYCODONE
CY1114803T1 (en) Sulfonamide pyrimidine derivatives as chemokine receptor regulators
BG66085B1 (en) Phenylalanine derivatives
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
EA200401227A1 (en) DELIVERY DELIVERY SYSTEM WITH CONTROLLED DELAY, INCLUDING PRAVASTATIN
SE0101932D0 (en) Pharmaceutical combinations
TR200101719T2 (en) The use of apomorphine in drug manufacture for the treatment of organic erectile dysfunction in men
DE60302157D1 (en) OPIOID RECEPTOR ANTAGONISTS
DK1678162T3 (en) Β-glycoprotein inhibitor, process for its preparation and pharmaceutical composition comprising it
SE0102440D0 (en) New compound
SE0401655D0 (en) New compounds
CY1105317T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
CY1105142T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
NO20051261L (en) Morphine-6-glukuronidsalt
CY1108238T1 (en) METHOD OF COMPOSITION OF PERINDOPRIL AND ITS PHARMACEUTICAL SALTS
NO20031410L (en) Use of distamycin derivatives for the manufacture of drugs